234 related articles for article (PubMed ID: 20235351)
21. [Cardio-renal syndrome and anaemia].
Jakić M
Acta Med Croatica; 2009 Sep; 63 Suppl 1():38-45. PubMed ID: 20232550
[TBL] [Abstract][Full Text] [Related]
22. Erythropoiesis-stimulating agents and heart failure.
Lipšic E; van der Meer P; van Veldhuisen DJ
Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
[TBL] [Abstract][Full Text] [Related]
23. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
Singh AK; Hertello P
Nephrol Nurs J; 2005; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
[TBL] [Abstract][Full Text] [Related]
24. Predictors of ESA use in the non-dialysis chronic kidney disease population with anemia.
Collins AJ; Guo H; Gilbertson DT; Bradbury BD
Nephron Clin Pract; 2009; 111(2):c141-8. PubMed ID: 19147996
[TBL] [Abstract][Full Text] [Related]
25. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
26. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome.
Iaina A; Silverberg DS; Wexler D
Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):95-100. PubMed ID: 16265380
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin in heart failure.
Silverberg DS; Wexler D; Blum M; Iaina A; Sheps D; Keren G; Schwartz D
Semin Nephrol; 2005 Nov; 25(6):397-403. PubMed ID: 16298262
[TBL] [Abstract][Full Text] [Related]
28. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
29. [Proactive approach to patients with chronic kidney disease--the role of general practitioner].
Bergman Marković B; Vrdoljak D; Kranjiević K
Acta Med Croatica; 2009 Sep; 63 Suppl 1():69-73. PubMed ID: 20232554
[TBL] [Abstract][Full Text] [Related]
30. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective.
Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C
Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957
[TBL] [Abstract][Full Text] [Related]
31. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?
Silverberg DS; Wexler D; Iaina A
J Nephrol; 2004; 17(6):749-61. PubMed ID: 15593047
[TBL] [Abstract][Full Text] [Related]
32. The treatment of anemia in chronic kidney disease: understandings in 2006.
Levin A
Curr Opin Nephrol Hypertens; 2007 May; 16(3):267-71. PubMed ID: 17420672
[TBL] [Abstract][Full Text] [Related]
33. [Cardioprotective effect of erythropoietin preparations in patients with chronic renal failure].
Nikolaev AIu; Ermolenko VM; Milovanova LIu; Milovanov IuS
Ter Arkh; 2004; 76(9):40-3. PubMed ID: 15532375
[TBL] [Abstract][Full Text] [Related]
34. The anemia of heart failure.
Silverberg DS; Wexler D; Palazzuoli A; Iaina A; Schwartz D
Acta Haematol; 2009; 122(2-3):109-19. PubMed ID: 19907148
[TBL] [Abstract][Full Text] [Related]
35. [Managing anaemia in kidney transplant patients with chronic kidney disease].
López Oliva MO; Del Castillo Caba D; Fernández Fresnedo G
Nefrologia; 2009; 29 Suppl 1():25-30. PubMed ID: 19675658
[TBL] [Abstract][Full Text] [Related]
36. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
37. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
Agarwal AK; Singh AK
Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
Rossert J; Gassmann-Mayer C; Frei D; McClellan W
Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
[TBL] [Abstract][Full Text] [Related]
39. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation.
Adamson JW
Adv Chronic Kidney Dis; 2009 Mar; 16(2):76-82. PubMed ID: 19233066
[TBL] [Abstract][Full Text] [Related]
40. Past, present, and future of chronic kidney disease anemia management in the United States.
Wish JB
Adv Chronic Kidney Dis; 2009 Mar; 16(2):101-8. PubMed ID: 19233069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
